AbbVie (ABBV) Operating Expenses (2012 - 2026)

AbbVie (ABBV) has reported Operating Expenses for 15 consecutive years, with $10.6 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Expenses changed 0.28% year-over-year to $10.6 billion in Q2 2026; TTM through Jun 2026 was $47.5 billion, a 0.33% change from a year earlier, with the FY2025 full-year figure at $46.1 billion, down 2.36% from the prior year.
• Operating Expenses was $10.6 billion for Q2 2026 at AbbVie, down from $11.0 billion in the prior quarter.
• Over five years, Operating Expenses peaked at $16.6 billion in Q4 2024 and troughed at $8.8 billion in Q1 2022.
• A 5-year average of $10.9 billion and a median of $10.5 billion in 2025 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses jumped 49.4% in 2024 and declined 27.23% in 2025, its largest moves.
• Over 5 years, Operating Expenses stood at $9.6 billion in 2022, then advanced by 15.46% to $11.1 billion in 2023, then jumped by 49.4% to $16.6 billion in 2024, then fell by 27.23% to $12.1 billion in 2025, then declined by 12.56% to $10.6 billion in 2026.
• The last three Operating Expenses figures came in at $10.6 billion (Q2 2026), $11.0 billion (Q1 2026), and $12.1 billion (Q4 2025), per Business Quant data.